QC Kinetix Welcomes Dr. Mitchell Sheinkop as National Medical Director
QC Kinetix, a trailblazer in regenerative medicine, has entered a groundbreaking new phase by appointing the distinguished orthopedic surgeon Dr. Mitchell Sheinkop as its National Medical Director. With this milestone, the company envisions a future marked by cutting-edge innovations and enhanced patient care.
Dr. Sheinkop brings over 40 years of expertise as a surgeon, educator, and authority in regenerative medicine. Excited to join QC Kinetix, he appreciates the company’s pioneering approach and transformative potential in revolutionizing regenerative medicine.
QC Kinetix has been on a fast growth trajectory, earning the No. 1 position on Franchise Times’ Fast & Serious List for 2024 and ranking No. 9 on Entrepreneur magazine’s Top New and Emerging Franchises for the same year.
“Joining QC Kinetix is an exciting opportunity to advance the field of regenerative medicine further,” Dr. Sheinkop shared. “I look forward to working with the team to develop new treatment protocols and improve patient care across all our clinics.”
About QC Kinetix
Headquartered in Charlotte, North Carolina, QC Kinetix is a franchise company specializing in regenerative medicine treatments that empower people to lead active lives. By offering non-surgical alternatives for addressing joint and musculoskeletal pain, QC Kinetix provides state-of-the-art biologic therapies that utilize the body’s natural healing abilities.
Since its first clinic opened in Charleston, South Carolina, in 2017, QC Kinetix has grown to include hundreds of clinics across over 100 cities in the U.S. With concierge-style facilities, the company provides innovative treatments, including alternatives to pain medications and surgeries, hair growth therapies, and men’s hormone replacement programs.
Dr. Sheinkop’s Role and Vision
As National Medical Director, Dr. Sheinkop will lead QC Kinetix’s medical management team, enhancing treatment protocols and spearheading research to maintain the company’s edge in regenerative medicine. His vision includes integrating physical therapy and weight loss programs into existing frameworks to optimize patient outcomes while refining training and certification standards for practitioners.
The CEO of QC Kinetix expressed enthusiasm for Dr. Sheinkop’s appointment:
“We are thrilled to welcome Dr. Sheinkop to our team. His vast experience, innovative mindset, and commitment to regenerative medicine make him the perfect leader for our medical team. His leadership will undoubtedly propel QC Kinetix to new levels of excellence.”
A Legacy of Excellence: Dr. Sheinkop’s Background
Dr. Sheinkop’s illustrious career spans clinical practice, research, and education. A Chicago native, he graduated from the University of Illinois and completed his medical training at Chicago Medical School and Northwestern University. His professional journey has taken him worldwide as a surgeon and lecturer, contributing extensively to orthopedics and regenerative medicine.
With over 70 published works in esteemed journals, Dr. Sheinkop is a recognized leader in his field. Reflecting on his career, he credits hard work, seizing opportunities, and a steadfast dedication to excellence.
Advancing Regenerative Medicine
Regenerative medicine has grown significantly over the past decade, shifting from disease management to therapies that stimulate the body’s natural ability to heal. Dr. Sheinkop has been instrumental in pioneering treatments that leverage natural biological tissues, helping patients achieve improved health and well-being through innovative methods.
Looking Ahead
QC Kinetix aims to expand its footprint to 250 locations across the United States by the end of 2024 while exploring international markets in the United Kingdom and Australia.
“As we grow, our focus will remain on being a leader and trusted voice in the regenerative medicine industry. We’re excited for what the future holds and the opportunity to change even more lives,” stated the CEO.
Under Dr. Sheinkop’s guidance, QC Kinetix is poised to achieve new milestones, reaffirming its commitment to delivering transformative care and redefining possibilities in regenerative medicine.
